{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:24:26Z","timestamp":1786933466498,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21ck0106648h"],"award-info":[{"award-number":["21ck0106648h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21ck0106648h"],"award-info":[{"award-number":["21ck0106648h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CDK12 and CDK13, two transcriptional cyclin-dependent kinases (CDKs), are emerging as therapeutic targets in epithelial cancers due to their vital roles in transcriptional elongation and maintaining genomic stability. However, the absence of predictive biomarkers may impede the clinical use of CDK12\/13 inhibitors. Here, we identify CDK10 as a consistent and kinase-dependent regulator of sensitivity to CDK12\/13 inhibition. A genome-wide CRISPR-Cas9 screen across six breast and ovarian cancer models reveals CDK10 loss as a top-ranked enhancer of response to the selective CDK12\/13 inhibitor CTX-439. Functional validation in multiple cancer cell lines and xenograft models shows that CDK10 deficiency boosts apoptotic responses and increases the antitumor effects of CDK12\/13 inhibition. Mechanistically, CDK10 loss extends the duration of CTX-439-induced transcriptional suppression and delays RNA polymerase II re-engagement at sensitive gene loci, exemplified by\n                    <jats:italic>CAPN7<\/jats:italic>\n                    and\n                    <jats:italic>SENP6<\/jats:italic>\n                    . These findings indicate CDK10 as a probable biomarker for patient stratification and as a co-target to boost the efficacy of transcriptional therapies. Our work reveals a previously underappreciated role for CDK10 in transcriptional resilience, emphasizing its potential to guide and enhance CDK12\/13-based cancer treatments.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08973-x","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:27:54Z","timestamp":1781144874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK10 loss primes tumor cells for transcriptional vulnerability and sensitizes to CDK12\/13 inhibition"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-6467","authenticated-orcid":false,"given":"Shafiqul","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6652-9618","authenticated-orcid":false,"given":"Yusuke","family":"Tarumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gohei","family":"Nishibuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5456-7643","authenticated-orcid":false,"given":"Hiroko","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-021X","authenticated-orcid":false,"given":"Kosuke","family":"Yusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"8973_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10:11.","journal-title":"Signal Transduct Target Ther"},{"key":"8973_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","volume":"22","author":"SJ Vervoort","year":"2022","unstructured":"Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. Nat Rev Cancer. 2022;22:5\u201324.","journal-title":"Nat Rev Cancer"},{"key":"8973_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"8973_CR4","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nsmb.2399","volume":"19","author":"S Larochelle","year":"2012","unstructured":"Larochelle S, Amat R, Glover-Cutter K, Sans\u00f3 M, Zhang C, Allen JJ, et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol. 2012;19:1108\u201315.","journal-title":"Nat Struct Mol Biol"},{"key":"8973_CR5","first-page":"928","volume":"35","author":"K Liang","year":"2015","unstructured":"Liang K, Gao X, Gilmore JM, Florens L, Washburn MP, Smith E, et al. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. MolCell Biol. 2015;35:928\u201338.","journal-title":"MolCell Biol"},{"key":"8973_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz5041","volume":"6","author":"Z Fan","year":"2020","unstructured":"Fan Z, Devlin JR, Hogg SJ, Doyle MA, Harrison PF, Todorovski I, et al. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Sci Adv. 2020;6:eaaz5041.","journal-title":"Sci Adv"},{"key":"8973_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09703-y","volume":"10","author":"M Krajewska","year":"2019","unstructured":"Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019;10:1757.","journal-title":"Nat Commun"},{"key":"8973_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","volume":"564","author":"SJ Dubbury","year":"2018","unstructured":"Dubbury SJ, Boutz PL, Sharp PA. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature. 2018;564:141\u20135.","journal-title":"Nature"},{"key":"8973_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 2020;10:351\u201370.","journal-title":"Cancer Discov"},{"key":"8973_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016;12:876\u201384.","journal-title":"Nat Chem Biol"},{"key":"8973_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, et al. Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer. Cancer Cell. 2019;36:545\u201358.","journal-title":"Cancer Cell"},{"key":"8973_CR12","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-18-1314","volume":"24","author":"PA Konstantinopoulos","year":"2018","unstructured":"Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: a trailblazing and transformative journey. Clin Cancer Res. 2018;24:4062\u20135.","journal-title":"Clin Cancer Res"},{"key":"8973_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu0847","volume":"11","author":"F Gui","year":"2025","unstructured":"Gui F, Jiang B, Jiang J, He Z, Tsujino T, Takai T, et al. Acute BRCAness induction and AR signaling blockage through CDK12\/7\/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. Sci Adv. 2025;11:eadu0847.","journal-title":"Sci Adv"},{"key":"8973_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"key":"8973_CR15","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","volume":"17","author":"SF Johnson","year":"2016","unstructured":"Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 2016;17:2367\u201381.","journal-title":"Cell Rep"},{"key":"8973_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4155\/fmc-2020-0240","volume":"13","author":"S Tadesse","year":"2021","unstructured":"Tadesse S, Duckett DR, Monastyrskyi A. The promise and current status of CDK12\/13 inhibition for the treatment of cancer. Future Med Chem. 2021;13:117\u201341.","journal-title":"Future Med Chem"},{"key":"8973_CR17","doi-asserted-by":"crossref","unstructured":"Yamakawa H, Khatab R, Mizutani A, Ebara S, Hirayama T, Tanaka S, et al. CDK12\/13 inhibitor, CTX-439, suppresses tumor growth and potentiates BCL-2 family blockade. Preprint at https:\/\/www.biorxiv.org\/content\/10.64898\/2026.02.20.706902v1.full 2026.","DOI":"10.64898\/2026.02.20.706902"},{"key":"8973_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","volume":"33","author":"AB Iniguez","year":"2018","unstructured":"Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, et al. EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell. 2018;33:202\u201316.","journal-title":"Cancer Cell"},{"key":"8973_CR19","first-page":"1913","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J\u3000Cancer Res. 2021;11:1913.","journal-title":"Am J\u3000Cancer Res"},{"key":"8973_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01648-x","volume":"25","author":"VE van der Noord","year":"2023","unstructured":"van der Noord VE, van der Stel W, Louwerens G, Verhoeven D, Kuiken HJ, Lieftink C, et al. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors. Breast Cancer Res. 2023;25:51.","journal-title":"Breast Cancer Res"},{"key":"8973_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2012.01.014","volume":"148","author":"JE Dancey","year":"2012","unstructured":"Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell. 2012;148:409\u201320.","journal-title":"Cell"},{"key":"8973_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, et al. Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer. 2025;24:156.","journal-title":"Mol Cancer"},{"key":"8973_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114603","volume":"240","author":"P Lei","year":"2022","unstructured":"Lei P, Zhang J, Liao P, Ren C, Wang J, Wang Y. Current progress and novel strategies that target CDK12 for drug discovery. Eur J Med Chem. 2022;240:114603.","journal-title":"Eur J Med Chem"},{"key":"8973_CR24","doi-asserted-by":"publisher","first-page":"50174","DOI":"10.18632\/oncotarget.15024","volume":"8","author":"VJ Guen","year":"2017","unstructured":"Guen VJ, Gamble C, Lees JA, Colas P. The awakening of the CDK10\/Cyclin M protein kinase. Oncotarget. 2017;8:50174.","journal-title":"Oncotarget"},{"key":"8973_CR25","doi-asserted-by":"publisher","first-page":"19525","DOI":"10.1073\/pnas.1306814110","volume":"110","author":"VJ Guen","year":"2013","unstructured":"Guen VJ, Gamble C, Flajolet M, Unger S, Thollet A, Ferandin Y, et al. CDK10\/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc Natl Acad Sci USA. 2013;110:19525\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8973_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/15384101.2016.1147632","volume":"15","author":"VJ Guen","year":"2016","unstructured":"Guen VJ, Gamble C, Perez DE, Bourassa S, Zappel H, G\u00e4rtner J, et al. STAR syndrome-associated CDK10\/Cyclin M regulates actin network architecture and ciliogenesis. Cell Cycle. 2016;15:678\u201388.","journal-title":"Cell Cycle"},{"key":"8973_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2008.01.001","volume":"13","author":"E Iorns","year":"2008","unstructured":"Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell. 2008;13:91\u2013104.","journal-title":"Cancer Cell"},{"key":"8973_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.gene.2012.01.022","volume":"498","author":"XY Zhong","year":"2012","unstructured":"Zhong XY, Xu XX, Yu JH, Jiang GX, Yu Y, Tai S, et al. Clinical and biological significance of Cdk10 in hepatocellular carcinoma. Gene. 2012;498:68\u201374.","journal-title":"Gene"},{"key":"8973_CR29","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3892\/or.2011.1617","volume":"27","author":"JH Yu","year":"2012","unstructured":"Yu JH, Zhong XY, Zhang WG, Wang ZD, Dong Q, Tai S, et al. CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol Rep. 2012;27:1266\u201376.","journal-title":"Oncol Rep"},{"key":"8973_CR30","first-page":"6812","volume":"17","author":"Y You","year":"2018","unstructured":"You Y, Bai F, Ye Z, Zhang N, Yao L, Tang Y, et al. Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis. Mol Med Rep. 2018;17:6812\u20138.","journal-title":"Mol Med Rep"},{"key":"8973_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655479","volume":"11","author":"ZA Bazzi","year":"2021","unstructured":"Bazzi ZA, Tai IT. CDK10 in gastrointestinal cancers: dual roles as a tumor suppressor and oncogene. Front Oncol. 2021;11:655479.","journal-title":"Front Oncol"},{"key":"8973_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715675","volume":"12","author":"T Akiyama","year":"2021","unstructured":"Akiyama T, Yamamoto T. Regulation of early lymphocyte development via mRNA decay catalyzed by the CCR4-NOT complex. Front Immunol. 2021;12:715675.","journal-title":"Front Immunol"},{"key":"8973_CR33","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607\u2013613.","journal-title":"Nucleic Acids Res"},{"key":"8973_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1612","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Shi SL. The roles of hnRNP A2\/B1 in RNA biology and disease. WIREs RNA. 2021;12:e1612.","journal-title":"WIREs RNA"},{"key":"8973_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fchem.2020.00147","volume":"8","author":"T Robert","year":"2020","unstructured":"Robert T, Johnson JL, Guichaoua R, Yaron TM, Bach S, Cantley LC, et al. Development of a CDK10\/CycM in vitro kinase screening assay and identification of first small-molecule inhibitors. Front Chem. 2020;8:147.","journal-title":"Front Chem"},{"key":"8973_CR36","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.210381","volume":"12","author":"R D\u00fcster","year":"2022","unstructured":"D\u00fcster R, Ji Y, Pan KT, Urlaub H, Geyer M. Functional characterization of the human Cdk10\/Cyclin Q complex. Open Biol. 2022;12:210381.","journal-title":"Open Biol"},{"key":"8973_CR37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nature03095","volume":"432","author":"C Sawyers","year":"2004","unstructured":"Sawyers C. Targeted cancer therapy. Nature. 2004;432:294\u20137.","journal-title":"Nature"},{"key":"8973_CR38","first-page":"PO.19.00086","volume":"3","author":"C Hu","year":"2019","unstructured":"Hu C, Dignam JJ. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis Oncol. 2019;3:PO.19.00086.","journal-title":"JCO Precis Oncol"},{"key":"8973_CR39","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1038\/537S63a","volume":"537","author":"V Prasad","year":"2016","unstructured":"Prasad V. Perspective: the precision-oncology illusion. Nature. 2016;537:S63.","journal-title":"Nature"},{"key":"8973_CR40","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159:1126\u201339.","journal-title":"Cell"},{"key":"8973_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01762-6","volume":"22","author":"E Thieme","year":"2023","unstructured":"Thieme E, Bruss N, Sun D, Dominguez EC, Coleman D, Liu T, et al. CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma. Mol Cancer. 2023;22:64.","journal-title":"Mol Cancer"},{"key":"8973_CR42","doi-asserted-by":"crossref","unstructured":"Pallasaho S, Gondane A, Duveau D, Thomas C, Loda M, Itkonen HM. Compromised CDK12 activity causes dependency on the non-essential spliceosome components. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.07.470703v1. 2021.","DOI":"10.1101\/2021.12.07.470703"},{"key":"8973_CR43","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1093\/nar\/gkad258","volume":"51","author":"V Panzeri","year":"2023","unstructured":"Panzeri V, Pieraccioli M, Cesari E, De La Grange P, Sette C. CDK12\/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1. Nucleic Acids Res. 2023;51:5512\u201326.","journal-title":"Nucleic Acids Res"},{"key":"8973_CR44","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1093\/nar\/gkad792","volume":"51","author":"Z Wang","year":"2023","unstructured":"Wang Z, Himanen SV, Haikala HM, Friedel CC, Vihervaara A, Barbori\u010d M. Inhibition of CDK12 elevates cancer cell dependence on P-TEFb by stimulation of RNA polymerase II pause release. Nucleic Acids Res. 2023;51:10970\u201391.","journal-title":"Nucleic Acids Res"},{"key":"8973_CR45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/PO.19.00399","volume":"4","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Velho PI, Fu W, Wang H, Agarwal N, Santos VS, et al. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD1 inhibitors. JCO Precis Oncol. 2020;4:370\u201381.","journal-title":"JCO Precis Oncol"},{"key":"8973_CR46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Gon\u00e7alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens. Nature. 2019;568:511\u20136.","journal-title":"Nature"},{"key":"8973_CR47","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 2016;17:1193\u2013205.","journal-title":"Cell Rep"},{"key":"8973_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07827-z","volume":"7","author":"SH Ong","year":"2017","unstructured":"Ong SH, Li Y, Koike-Yusa H, Yusa K. Optimised metrics for CRISPR-KO screens with second-generation gRNA libraries. Sci Rep. 2017;7:7384.","journal-title":"Sci Rep"},{"key":"8973_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014;15:554.","journal-title":"Genome Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08973-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08973-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08973-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T01:41:00Z","timestamp":1786930860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08973-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8973"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08973-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AM, HY and DM are employees of Chordia Therapeutics, Inc. KY received a collaboration research grant from Chordia. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of the Shonan Health Innovation Park (AU-00031007). The care and use of animals were conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"737"}}